May 09, 2019 Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting
May 07, 2019 GenSight Biologics announces positive Data Safety Monitoring Board review and continuation of PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa
May 06, 2019 GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)